developer

Filana Therapeutics

13/10/2023 13:57

** Shares of Cassava Sciences  SAVA.O  fall ~24% to $13.33
premarket
    ** According to a report from American Association for the
Advancement of Science (AAAS), co-developer of Cassava’s
potential Alzheimer’s drug simufilam is being accused of
scientific misconduct
    ** The report says an investigation committee from the City
University of New York accused Hoau-Yan Wang with fabrication in
research papers that supported simufilam
    ** Says, committee found numerous signs of image
manipulation that suggested that simufilam can blunt the effects
of beta amyloid, a protein that triggers Alzheimer’s disease 
    ** The doubts concerning SAVA's drug began two years ago and
was followed by an investigation by the U.S. SEC in November
2021
    ** Up to last close, shares down 40.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))